重大事件
即時報告
8-K
2026-07-01
Gossamer Bio 公布2030年到期可轉換票據轉換率及認股權證行使價
AI 繁中摘要
Gossamer Bio 公佈 7.50% 可轉換優先擔保第一留置權票據（2030 年到期）之轉換率及認股權證行使價 🏢📄
2026 年 7 月 1 日，Gossamer Bio, Inc.（納斯達克：GOSS）宣佈其 2030 年到期的 7.50% 可轉換優先擔保第一留置權票據之初始轉換率。每 1,000 美元本金額可轉換為 5,347.5936 股普通股，相當於每股轉換價約 0.19 美元。同時，認股權證（Purchase Warrants）的初始行使價定為每股 0.34 美元。
以上數字是根據 2026 年 6 月 22 日起七個交易日的「參考價格」計算得出，該參考價格為 0.17 美元。轉換率計算方式為：較低者為 (i) 5,347.5936 或 (ii) 1,000 除以參考價格的 110%；認股權證行使價則為較高者：(i) 0.34 美元或 (ii) 參考價格的 125%。
Gossamer Bio 是一家專注於開發治療肺動脈高壓（PAH）及間質性肺病相關肺高壓（PH-ILD）藥物 seralutinib 的生物製藥公司。是次公告僅供參考，不構成任何證券的出售要約或購買要約邀請。
對投資者的潛在影響：轉換價格及認股權證行使價均與普通股參考價格掛鈎，反映公司當前的股價水平。投資者應留意轉換權可能帶來的股權攤薄效應，以及認股權證未來對股價的影響。
展開英文正文
EX-99.1 2 goss-20260701xexx991xprcon.htm EX-99.1 Document Exhibit 99.1 Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants San Diego, California. (July 1, 2026) – Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 (the “2030 Convertible Notes”) will be 5,347.5936 shares of the Company’s common stock per $1,000 principal amount of the 2030 Convertible Notes, which represents a conversion price of approximately $0.19 per share of common stock, and the initial exercise price of its warrants to purchase shares of common stock (the “Purchase Warrants”) will be $0.34 per whole share of its common stock. The “Reference Price,” which was calculated over a seven trading-day period beginning on June 22, 2026 in accordance with the terms of the 2030 Convertible Notes and Purchase Warrants, was determined to be $0.17. The initial conversion rate applicable to the 2030 Convertible Notes was calculated as the lesser of (i) 5,347.5936 and (ii) 1,000 divided by 110% of the Reference Price. The initial exercise price applicable to the Purchase Warrants was calculated as the greater of (i) $0.34 and (ii) 125% of the Reference Price. This press release is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any securities referred to in this press release. About Gossamer Bio Gossamer Bio is a biopharmaceutical company focused on the development of treatments for pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension. For Investors and Media: Bryan Giraudo, Chief Financial Officer & Chief Operating Officer Gossamer Bio Investor Relations [email protected]